Philip W Kantoff

Philip W Kantoff

UNVERIFIED PROFILE

Are you Philip W Kantoff?   Register this Author

Register author
Philip W Kantoff

Philip W Kantoff

Publications by authors named "Philip W Kantoff"

Are you Philip W Kantoff?   Register this Author

100Publications

3815Reads

26Profile Views

Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry.

Prostate Cancer Prostatic Dis 2019 09 14;22(3):420-427. Epub 2019 Jan 14.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41391-018-0121-2
Publisher Site
http://dx.doi.org/10.1038/s41391-018-0121-2DOI Listing
September 2019

Methylation-associated miR-193b silencing activates master drivers of aggressive prostate cancer.

Mol Oncol 2019 Sep 19;13(9):1944-1958. Epub 2019 Jul 19.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/1878-0261.12536DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717747PMC
September 2019

Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities.

Eur Urol 2019 Aug 2. Epub 2019 Aug 2.

Department of Medical Oncology, Sidney Kimmel Cancer Center at Jefferson, Sidney Kimmel Medical College, Philadelphia, PA, USA; Sidney Kimmel Cancer Center at Jefferson, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03022838193058
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2019.07.031DOI Listing
August 2019

Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types.

Clin Cancer Res 2019 Jul 22;25(14):4290-4299. Epub 2019 Apr 22.

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-0404DOI Listing
July 2019

Aneuploidy drives lethal progression in prostate cancer.

Proc Natl Acad Sci U S A 2019 Jun 13;116(23):11390-11395. Epub 2019 May 13.

David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1902645116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561291PMC
June 2019

Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications.

Eur J Cancer 2019 May 6;112:118-126. Epub 2019 Mar 6.

HealthCore-NERI, 480 Pleasant Street, Watertown, MA 02472, USA; Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.11.033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501826PMC
May 2019

Time to Prostate-specific Antigen Nadir and the Risk of Death From Prostate Cancer Following Radiation and Androgen Deprivation Therapy.

Urology 2019 04 18;126:145-151. Epub 2019 Jan 18.

Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2018.11.056DOI Listing
April 2019

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

Eur Urol 2019 01 16;75(1):88-99. Epub 2018 Apr 16.

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, MD, USA; Department of Urology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.03.028DOI Listing
January 2019

A Prospective Study of Aspirin Use and Prostate Cancer Risk by Status.

Cancer Epidemiol Biomarkers Prev 2018 10 14;27(10):1231-1233. Epub 2018 Aug 14.

National Cancer Institute, Division of Cancer Epidemiology and Genetics, Epidemiology and Biostatistics Program, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-18-0510DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6170677PMC
October 2018

Regular aspirin use and gene expression profiles in prostate cancer patients.

Cancer Causes Control 2018 Aug 18;29(8):775-784. Epub 2018 Jun 18.

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10552-018-1049-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298857PMC
August 2018

Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer.

J Endocr Soc 2018 May 20;2(5):485-496. Epub 2018 Apr 20.

Research Program in Men's Health: Aging and Metabolism, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/js.2018-00039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941157PMC
May 2018

Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer.

Cancer 2018 04 16;124(7):1391-1399. Epub 2018 Jan 16.

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31217
Publisher Site
http://dx.doi.org/10.1002/cncr.31217DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982532PMC
April 2018

Current treatment strategies for advanced prostate cancer.

Int J Urol 2018 03 20;25(3):220-231. Epub 2017 Dec 20.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/iju.13512DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053280PMC
March 2018

Is the Evidence Sufficient to Recommend Statins for All Men With Prostate Cancer?

J Clin Oncol 2017 10 17;35(29):3272-3274. Epub 2017 Aug 17.

Lorelei A. Mucci, Harvard TH Chan School of Public Health, Boston, MA; and Philip W. Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.7915DOI Listing
October 2017

Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer.

PLoS One 2017 8;12(9):e0184166. Epub 2017 Sep 8.

Division of Urology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0184166PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590894PMC
October 2017

Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.

J Clin Oncol 2017 09 10;35(27):3097-3104. Epub 2017 Aug 10.

Wanling Xie, Meredith M. Regan, and Christopher J. Sweeney, Dana-Farber Cancer Institute, Boston, MA; Marc Buyse, International Drug Development Institute; Bertrand Tombal, Université Catholique de Louvain, Louvain-la-Neuve; Laurence Collette, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Susan Halabi, Duke University Medical Center, Durham, NC; Philip W. Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; Oliver Sartor, Tulane Medical School, New Orleans, LA; Howard Soule, Prostate Cancer Foundation, Santa Monica; Howard M. Sandler, Cedars-Sinai Medical Center, Los Angeles, CA; Noel W. Clarke, The Christie NHS Foundation Trust, Manchester; Matthew R. Sydes, University College London, London, United Kingdom; James J. Dignam, University of Chicago, Chicago, IL; Karim Fizazi, Institut Gustave-Roussy, Villejuif, France; Wendy R. Paruleker, Canadian Cancer Trials Group, Kingston, Ontario, Canada; and Scott G. Williams, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.9987DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652387PMC
September 2017

Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer.

J Clin Oncol 2017 01 30;35(1):124-125. Epub 2016 Sep 30.

Philip W. Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; James L. Gulley, National Cancer Institute, Bethesda, MD; and Cesar Pico-Navarro, Bavarian Nordic, Redwood City, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.7748DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411419PMC
January 2017

Cancer nanomedicine: progress, challenges and opportunities.

Nat Rev Cancer 2017 01 11;17(1):20-37. Epub 2016 Nov 11.

Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc.2016.108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575742PMC
January 2017

Physical and emotional health information needs and preferences of long-term prostate cancer survivors.

Patient Educ Couns 2016 12 14;99(12):2049-2054. Epub 2016 Jul 14.

Perini Family Survivors' Center, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA; Department of Pediatrics, Harvard Medical School, 25 Shattuck Street, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pec.2016.07.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675563PMC
December 2016

Prostate-Specific Antigen Failure and Risk of Death Within Comorbidity Subgroups Among Men With Unfavorable-Risk Prostate Cancer Treated in a Randomized Trial.

J Clin Oncol 2016 11;34(31):3781-3786

Nicholas J. Giacalone, Marian Loffredo, and Anthony V. D'Amico, Brigham and Women's Hospital/Dana-Farber Cancer Institute; Nicholas J. Giacalone, Harvard Radiation Oncology Program, Boston, MA; Jing Wu and Ming-Hui Chen, University of Connecticut, Storrs, CT; Andrew Renshaw, Miami Baptist Hospital, Miami, FL; and Philip W. Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.4530DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791839PMC
November 2016

Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center.

Clin Genitourin Cancer 2016 08 17;14(4):e299-305. Epub 2015 Dec 17.

Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2015.12.008DOI Listing
August 2016

Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma.

Clin Genitourin Cancer 2016 08 24;14(4):352-9. Epub 2015 Dec 24.

Bladder Cancer Center, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2015.12.029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508512PMC
August 2016

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

N Engl J Med 2016 Aug 6;375(5):443-53. Epub 2016 Jul 6.

From the University of Washington (C.C.P., M. Beightol, C.M., B.N., H.H.C., B.M., T.W., S. Casadei, P.S.N.) and Fred Hutchinson Cancer Research Center (N.D.S., R.G., P.S.N.) - both in Seattle; the Institute of Cancer Research and Royal Marsden Hospital, London (J.M., S. Carreira, R.E., J.B.); Memorial Sloan Kettering Cancer Center (M.F.W., W.A., M. Berger, L.Z., A.Z., J. Vijai, H.I.S., C.S., N.S., P.W.K., D.S., M.R., K.O.), Weill Cornell Medical College (H.B., O.E., M.A.R.), and the Prostate Cancer Clinical Trials Consortium (J. Vinson, J.F.) - all in New York; the University of Michigan, Ann Arbor (D.R., R.L., M.H., A.C.); Howard Hughes Medical Institute, Chevy Chase, MD (A.C., C.S.); and Dana-Farber Cancer Institute, Boston (A.G., L.G., M.-E.T., S.A., G.C.H., E.M.V.A.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1603144DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986616PMC
August 2016

A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy.

J Clin Oncol 2016 06 4;34(16):1913-20. Epub 2016 Apr 4.

Rana R. McKay, Lillian Werner, Christopher J. Sweeney, Philip W. Kantoff, and Mary-Ellen Taplin, Dana-Farber Cancer Institute, Boston; Robert W. Ross, Bluebird Bio, Cambridge, MA; Amado J. Zurita and Hai T. Tran, MD Anderson Cancer Center, Houston, TX; Justine Y. Bruce, University of Wisconsin Carbone Cancer Center, Madison, WI; Michael A. Carducci, Johns Hopkins University; Arif Hussain, Greenebaum Cancer Center, Baltimore, MD; Mark N. Stein, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Elisabeth I. Heath, Karmanos Cancer Institute, Detroit, MI; and Philip W. Kantoff and Susan F. Slovin, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.3154DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321094PMC
June 2016

Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis.

Prostate 2016 May 5;76(7):691-9. Epub 2016 Feb 5.

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23160DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510241PMC
May 2016

Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.

Proc Natl Acad Sci U S A 2016 May 16;113(22):6259-64. Epub 2016 May 16.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215; Harvard Medical School, Boston, MA 02215

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1600420113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896695PMC
May 2016

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

J Clin Oncol 2016 Apr 22;34(12):1402-18. Epub 2016 Feb 22.

Howard I. Scher, Michael J. Morris, Dana E. Rathkopf, and Susan F. Slovin, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College; David Nanus, NewYork Presbyterian Weill Cornell Medical Center; Lawrence W. Schwartz, NewYork Presbyterian Columbia University Medical Center, New York, NY; Walter M. Stadler, University of Chicago Medicine, Chicago, IL; Celestina Higano and Peter S. Nelson, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA; Ethan Basch, University of North Carolina at Chapel Hill, Chapel Hill, NC; Emmanual S. Antonarakis and Michael A. Carducci, Johns Hopkins University School of Medicine, Baltimore, MD; Tomasz M. Beer, Oregon Health and Science University, Portland, OR; Paul G. Corn and Christopher Logothetis, MD Anderson Cancer Center, Houston, TX; Robert Dreicer, University of Virginia School of Medicine, Charlottesville, VA; Daniel J. George, Susan Halabi, and Andrew J. Armstrong, Duke University and Duke Cancer Institute, Durham, NC; Elisabeth I. Heath, Wayne State University Karmanos Cancer Institute, Detroit; and Maha Hussain, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Wm. Kevin Kelly, Sidney Kimmel School of Medicine at Thomas Jefferson University, Philadelphia, PA; Glenn Liu and George Wilding, University of Wisconsin Carbone Cancer Center, Madison, WI; Mark N. Stein, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ; Charles S. Ryan and Eric J. Small, University of California Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Oliver Sartor, Tulane School of Medicine, New Orleans, LA; Matthew Raymond Smith, Massachusetts General Hospital Cancer Center and Harvard Medical School; Mary-Ellen Taplin and Philip W. Kantoff, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, Franc

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.2702DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872347PMC
April 2016

Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer--Reply.

JAMA 2016 Mar;315(10):1055-6

Department of Medicine, Dana Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2015.17570DOI Listing
March 2016

Integrative analyses reveal a long noncoding RNA-mediated sponge regulatory network in prostate cancer.

Nat Commun 2016 Mar 15;7:10982. Epub 2016 Mar 15.

Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms10982DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796315PMC
March 2016

Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity.

Clin Cancer Res 2015 Dec 19;21(24):5578-87. Epub 2015 Aug 19.

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0824DOI Listing
December 2015

Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.

Can J Urol 2015 Dec;22(6):8048-55

University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

View Article

Download full-text PDF

Source
December 2015

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

N Engl J Med 2015 Nov 25;373(19):1814-23. Epub 2015 Sep 25.

From the Dana-Farber Cancer Institute, Boston (T.K.C., P.W.K.); Institut Gustave Roussy, Villejuif, France (B.E.); Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, London (T.P.); Icon Cancer Care, South Brisbane, QLD, Australia (P.N.M.); Cleveland Clinic, Cleveland (B.I.R.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (H.H.); Texas Oncology-Charles A. Sammons Cancer Center, Baylor University, Dallas (T.E.H.); University of Ulsan College of Medicine (J.-L.L.) and Seoul National University Hospital (B.K.) - both in Seoul, South Korea; Helsinki University Central Hospital Cancer Center, Helsinki (K.P.); Washington University in St. Louis, St. Louis (B.J.R.); Sunnybrook Odette Cancer Centre, Toronto (G.A.B.), and Tom Baker Cancer Centre, Calgary, AB (D.Y.C.H.) - both in Canada; National Institute of Oncology, Budapest, Hungary (L.G.); Hospital de la Santa Creu i Sant Pau, Barcelona (P.M.); Medical University of Vienna, Vienna (M.S.); Exelixis, South San Francisco, CA (A.B-H., C.H., C.S., G.M.S.); University of Texas M.D. Anderson Cancer Center, Houston (N.M.T.); and the Memorial Sloan Kettering Cancer Center, New York (R.J.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1510016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024539PMC
November 2015

Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations.

JAMA 2015 Nov;314(19):2077-9

Center for Surgery and Public Health, Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2015.7273DOI Listing
November 2015

Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer.

Mol Cancer Res 2015 Oct 29;13(10):1431-40. Epub 2015 Jun 29.

Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Broad Institute of Harvard and MIT, Cambridge, Massachusetts. Division of Cancer Studies, King's College London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-14-0569DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618038PMC
October 2015

Long-term Follow-up of a Randomized Trial of Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.

JAMA 2015 Sep 22-29;314(12):1291-3

Department of Medicine, Dana Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2015.8577DOI Listing
October 2015

GermLine Variation in Superoxide Dismutase-2 (SOD2) and Survival Outcomes After Radiation Therapy for Prostate Cancer: Results of a Test and Validation Set Analysis.

Clin Genitourin Cancer 2015 Aug 3;13(4):370-377.e1. Epub 2015 Jan 3.

Department of Epidemiology, Harvard School of Public Health, Boston, MA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673140029
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2014.12.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5038132PMC
August 2015

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Authors:
Ayalew Tefferi Hagop Kantarjian S Vincent Rajkumar Lawrence H Baker Jan L Abkowitz John W Adamson Ranjana Hira Advani James Allison Karen H Antman Robert C Bast John M Bennett Edward J Benz Nancy Berliner Joseph Bertino Ravi Bhatia Smita Bhatia Deepa Bhojwani Charles D Blanke Clara D Bloomfield Linda Bosserman Hal E Broxmeyer John C Byrd Fernando Cabanillas George Peter Canellos Bruce A Chabner Asher Chanan-Khan Bruce Cheson Bayard Clarkson Susan L Cohn Gerardo Colon-Otero Jorge Cortes Steven Coutre Massimo Cristofanilli Walter J Curran George Q Daley Daniel J DeAngelo H Joachim Deeg Lawrence H Einhorn Harry P Erba Francisco J Esteva Elihu Estey Isaiah J Fidler James Foran Stephen Forman Emil Freireich Charles Fuchs James N George Morie A Gertz Sergio Giralt Harvey Golomb Peter Greenberg Jordan Gutterman Robert I Handin Samuel Hellman Paulo Marcelo Hoff Ronald Hoffman Waun Ki Hong Mary Horowitz Gabriel N Hortobagyi Clifford Hudis Jean Pierre Issa Bruce Evan Johnson Philip W Kantoff Kenneth Kaushansky David Khayat Fadlo R Khuri Thomas J Kipps Margaret Kripke Robert A Kyle Richard A Larson Theodore S Lawrence Ross Levine Michael P Link Scott M Lippman Sagar Lonial Gary H Lyman Maurie Markman John Mendelsohn Neal J Meropol Yoav Messinger Therese M Mulvey Susan O'Brien Roman Perez-Soler Raphael Pollock Josef Prchal Oliver Press Jerald Radich Kanti Rai Saul A Rosenberg Jacob M Rowe Hope Rugo Carolyn D Runowicz Brenda M Sandmaier Alan Saven Andrew I Schafer Charles Schiffer Mikkael A Sekeres Richard T Silver Lillian L Siu David P Steensma F Marc Stewart Wendy Stock Richard Stone Rainer Storb Louise C Strong Martin S Tallman Michael Thompson Naoto T Ueno Richard A Van Etten Julie M Vose Peter H Wiernik Eric P Winer Anas Younes Andrew D Zelenetz Charles A LeMaistre

Mayo Clin Proc 2015 Aug 23;90(8):996-1000. Epub 2015 Jul 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2015.06.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365030PMC
August 2015

Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease.

J Urol 2015 Jul 24;194(1):91-7. Epub 2015 Jan 24.

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2015.01.078DOI Listing
July 2015

Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.

JAMA Oncol 2015 Jul;1(4):495-504

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts2Gelb Center for Translational Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.0829DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554437PMC
July 2015

The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.

Chem Biol Interact 2015 Jun 13;234:332-8. Epub 2014 Dec 13.

Centers for Cancer Pharmacology and Excellence of Environmental Toxicology (CEET), Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-6160, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00092797140039
Publisher Site
http://dx.doi.org/10.1016/j.cbi.2014.12.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414681PMC
June 2015

Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.

J Clin Oncol 2015 Apr 26;33(12):1356-63. Epub 2015 Jan 26.

Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.3875DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881370PMC
April 2015

Emerging players in prostate cancer: long non-coding RNAs.

Am J Clin Exp Urol 2014 25;2(4):294-9. Epub 2014 Dec 25.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4297325PMC
January 2015

Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.

J Clin Oncol 2014 Nov 13;32(33):3705-15. Epub 2014 Oct 13.

Mary-Ellen Taplin, Massimo Loda, Rosina T. Lis, Wanling Xie, Zhenyang Jiang, and Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School; Glenn J. Bubley, Huihui Ye, and Steven P. Balk, Beth Israel Deaconess Medical Center; Jerome P. Richie, Massimo Loda, and Rosina T. Lis, Brigham and Women's Hospital, Boston, MA; Bruce Montgomery, Bruce L. Dalkin, Lawrence D. True, and Alvin M. Matsumoto, University of Washington; Brett T. Marck and Alvin M. Matsumoto, Geriatric Research, Education and Clinical Center, Veterans' Affairs Puget Sound Health Care System; Elahe A. Mostaghel and Peter S. Nelson, Fred Hutchinson Cancer Research Center, Seattle, WA; Christopher J. Logothetis, John W. Davis, and Patricia Troncoso, University of Texas MD Anderson Cancer Center, Houston, TX; Martin G. Sanda, Emory University School of Medicine, Atlanta, GA; Massimo Loda, King's College London, London, United Kingdom; Trevor M. Penning and Daniel Tamae, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; and Christopher M. Haqq, NamPhuong Tran, Weimin Peng, Thian Kheoh, and Arturo Molina, Janssen Research and Development, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.4578DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226804PMC
November 2014